Streetbeat News

Regulatory

GILD

Gilead Sciences announced promising results from a Phase 3 trial of its HIV-1 capsid inhibitor, lenacapavir, showing a 96% reduction in HIV infections. The trial demonstrated lenacapavir's superiority over Gilead's Truvada, leading to early unblinding of the study. Gilead plans regulatory filings by 2024, aiming for a 2025 launch.

Portfolio Pulse from Vandana Singh

September 12, 2024 | 5:46 pm

MRNA

NVAX

Novavax shares are trading lower despite FDA approval of its updated COVID-19 vaccine, due to reduced 2024 revenue guidance. Moderna also reported lower revenue projections but remains confident in long-term growth.

Portfolio Pulse from Vaishali Prayag

September 12, 2024 | 5:45 pm

LI

NIO

XPEV

US-listed Chinese EV companies' shares are declining due to reports that the European Commission rejected price adjustment offers to avoid tariffs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:44 pm

WNW

Meiwu Technology's shares are declining following a Nasdaq notification about its bid price deficiency.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 5:06 pm

GBTC

Grayscale Investments has launched a new XRP Trust after a 3-year hiatus, following a court ruling that XRP is not a security when sold on secondary markets. This move marks a shift in Grayscale's stance since the 2020 SEC lawsuit against Ripple Labs.

Portfolio Pulse from Murtuza Merchant

September 12, 2024 | 4:50 pm

BTCUSD

Daniel Batten highlights 19 lesser-known benefits of Bitcoin, focusing on its humanitarian, energy, environmental, and democratic impacts. These benefits include aiding war refugees, reducing emissions, and fostering financial inclusion.

Portfolio Pulse from Khyathi Dalal

September 12, 2024 | 4:39 pm

XFIN

Excelfin Acquisition Corp. has received a notice of non-compliance with Nasdaq's listing rule as of September 11. This could impact its stock price and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:36 pm

CING

Cingulate shares are trading lower following the announcement of the commencement of a final FDA-required food effect study for CTx-1301, a treatment for ADHD.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:20 pm

NVDA

SPY

Nvidia CEO Jensen Huang expressed confidence in the Biden administration's decision-making following a White House meeting. He emphasized the importance of American technology in the new industrial revolution.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:13 pm

F

GM

TSLA

Automakers express concerns over a proposed bill that would tighten restrictions on Chinese content for electric vehicle tax credits, potentially requiring a rollback of emissions rules.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 4:10 pm